XCNQPREV
Market cap9mUSD
Dec 23, Last price
0.03CAD
1D
0.00%
1Q
66.67%
IPO
-67.95%
Name
Preveceutical Medical Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.92%
Rev. gr., 5y
-12.64%
Revenues
0k
Net income
-1m
L-13.97%
CFO
-297k
L+33.39%
Profile
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; BSV Peptide Program for targeting cancer progression; Non-Addictive Analgesic for pain management; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑07 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 629 | 472 | 898 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (629) | (472) | (898) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (1) | (20) | |||||||
Tax Rate | |||||||||
NOPAT | (629) | (472) | (877) | ||||||
Net income | (1,274) -13.97% | (1,481) -14.20% | (1,727) -54.58% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (6) | ||||||||
BB yield | 0.05% | ||||||||
| Debt | |||||||||
Debt current | 3,834 | 3,232 | 1,253 | ||||||
Long-term debt | 1,676 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 3,833 | 3,226 | 2,913 | ||||||
| Cash flow | |||||||||
Cash from operating activities | (297) | (223) | (426) | ||||||
CAPEX | 4 | (55) | |||||||
Cash from investing activities | 850 | (53) | |||||||
Cash from financing activities | 294 | 212 | 137 | ||||||
FCF | (96) | (195) | (248) | ||||||
| Balance | |||||||||
Cash | 1 | 6 | 16 | ||||||
Long term investments | |||||||||
Excess cash | 1 | 6 | 16 | ||||||
Stockholders' equity | (5,778) | (4,635) | (8,580) | ||||||
Invested Capital | 3,834 | 3,232 | 7,405 | ||||||
ROIC | |||||||||
ROCE | 32.34% | 33.62% | 76.43% | ||||||
| EV | |||||||||
Common stock shares outstanding | 535,303 | 521,790 | 507,953 | ||||||
Price | 0.03 0.00% | 0.03 0.00% | 0.03 -16.67% | ||||||
Market cap | 13,383 2.59% | 13,045 2.72% | 12,699 -7.11% | ||||||
EV | 17,215 | 16,271 | 15,612 | ||||||
EBITDA | (619) | (462) | (893) | ||||||
EV/EBITDA | |||||||||
Interest | 310 | 237 | 467 | ||||||
Interest/NOPBT | |||||||||